Floatz logo

Oncolytic Adenovirus Ad5-Dnx-2401

Recurrent Anaplastic Astrocytoma

M.D. Anderson Cancer Centergene_therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

36 Active assets in the Recurrent Anaplastic Astrocytoma cohort.

Asset / SponsorPhaseRating
Irinotecan
City of Hope Medical Center
Phase 2/3BBB
Cediranib
National Cancer Institute (NCI)
Phase 2BBB
(+)-VINCRISTINE
Novartis Pharmaceuticals
Phase 2/3BB
Carboplatin
Oliver Jonas
Phase 2BB
gsk1120212
National Cancer Institute (NCI)
Phase 4BB

View all 50 →

Same molecule, other indications

Oncolytic Adenovirus Ad5-Dnx-2401 is also rated in:

IDH-wildtype glioblastomaDormant
CC
Indicative ·
43 / 100
View asset →
gliosarcomaDormant
CC
Indicative ·
43 / 100
View asset →
malignant gliomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →